Viewing Study NCT06644495


Ignite Creation Date: 2025-12-24 @ 1:58 PM
Ignite Modification Date: 2026-01-01 @ 12:31 AM
Study NCT ID: NCT06644495
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-10-16
First Post: 2024-10-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
Sponsor: Qilu Pharmaceutical Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Outcomes Module Eligibility Module Contacts Locations Module